Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glembatumumab Vedotin in Recurrent or Refractory Osteosarcoma
NCT02487979Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Jun 2017
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of glembatumumab vedotin in osteosarcoma (OS), sponsored by National Cancer Institute. Started Feb 2016; status: completed.
02
Drugs
glembatumumab vedotin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02487979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487979.